Ottobock Announces IPO Pricing and Future Growth Plans

Ottobock SE & Co. KGaA (the “Company”) – recognized globally as a leading MedTech innovator in the Custom Orthotics and Prosthetics (O&P) industry – has announced the final pricing for its initial public offering (the “IPO”), setting the share price at EUR 66.00. This significant step brings Ottobock to a new phase in its history, opening up opportunities for growth and further innovation.

The offering includes a total of 12,236,173 shares being distributed to investors. Of these, 1,515,151 are newly issued bearer shares resulting from a capital increase through cash contributions. Additionally, 9,125,000 existing bearer shares are being offered from the holdings of Näder Upside Vermögensverwaltungs GmbH (the “Selling Shareholder”). An extra 1,596,022 existing bearer shares from the Selling Shareholder are available as part of an over-allotment option, often referred to as the “Greenshoe Option”.

Ottobock’s CEO, Oliver Jakobi, commented on this milestone: “The IPO marks an important milestone for Ottobock. For more than 100 years, the Company has stood for innovation and responsibility towards the people we serve. With the IPO, we are creating the foundation to carry this tradition into the future – with investments in cutting-edge technologies, sustainable growth, and the clear ambition to set new standards in Human Bionics.”

Taking the final offer price as the basis, and assuming the Greenshoe Option is fully exercised, the total placement volume will reach EUR 807,587,418.00. Ottobock's market capitalization at listing is projected to be around EUR 4.2 billion. The anticipated free float (the proportion of shares available for trading) is expected to stand at 19.12% under full exercise of the Greenshoe Option, with existing shareholders retaining at least 80.88% of Ottobock’s share capital.

Retail investors participating through syndicate banks have been allocated roughly 4.7% of the total shares on offer, equating to an aggregate of 574,145 shares. The allocation followed a transparent structure: each retail order up to 20 shares was filled in full, while orders above this amount received approximately 12% allocation for shares over the initial 20, up to a maximum of 500 shares per order. This allocation process adhered to the “Principles for the Allotment of Share Issues to Private Investors” as issued by the German Commission of Stock Exchange Experts, ensuring all syndicate banks and their affiliates followed the same fair guidelines.

To provide stability and confidence to new investors, the Company, its existing shareholders, and certain governing body members are all subject to a 180-day lock-up period following the first trading day. Trading of Ottobock's shares on the regulated market (Prime Standard) of the Frankfurt Stock Exchange is scheduled to begin on 9 October 2025 under the trading symbol OBCK and the ISIN . Settlement and closing of the offering are expected to occur on 10 October 2025.

A consortium of renowned financial institutions is managing the offering: BNP PARIBAS, Deutsche Bank, and Goldman Sachs are serving as joint global coordinators and joint bookrunners. BofA Securities and UBS act as senior bookrunners, with Jefferies and UniCredit as additional joint bookrunners. COMMERZBANK fills the role of senior co-lead manager, while DZ BANK and LBBW act as co-lead managers. Financial advisory support to Näder Holding and Ottobock is being provided by Lilja & Co.

For more details and updates, please visit: https://investors.ottobock.com.

About Ottobock

Ottobock is a global MedTech leader, seamlessly blending over a century of tradition with remarkable innovation in prosthetics, neuro-orthotics, and exoskeleton technologies. The company specializes in advanced solutions designed to enhance mobility for individuals facing physical limitations and is at the forefront of driving digital transformation in the O&P industry. Founded in Berlin in 1919, Ottobock now operates in 45 countries with nearly 9,300 employees worldwide (FTEs) and runs the world's largest international patient care network with approximately 400 clinics. The company is shaping the next generation of human bionics, boasting a robust R&D pipeline and a portfolio of over 2,600 patents and patent applications. Ottobock’s mission is deeply embedded in its values: improving freedom of movement, quality of life, and independence for its users. Furthermore, Ottobock is committed to social responsibility, serving as a partner and supporter of the Paralympic Games since 1988.